UK-based biotechnology firm ReGen Therapeutics says that data from a study of its novel formulation of zolpidem indicate that the drug is non-sedating. The firm explained that the assessment had been designed to examine the antidormancy effects of the drug in conscious, fully-perceptive ambulant patients who have various disabilities as a result of brain damage.
The drug, which is an off-patent sedative that was formally marketed by French drug major Sanofi-Aventis under the brand names Stilnox and Ambien (Marketletters passim), was examined in a Phase II placebo-controlled study at sites in the UK and South Africa, where its antidormancy effect was first identified.
The results showed that the 2.5mg dosage, delivered in the form of a sublingual spray, was no more sedating than placebo, while the 5mg and 10mg formulations were sedative in a dose dependant manner. The trial also demonstrated that the spray version of the product had a faster onset of action than tablet versions of the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze